Clinical Trials · NCT05638594

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Name: Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Recruiting
Sponsor: Shengjing Hospital
Enrollment: 236
Start date: Dec 2022
Locations: 1 site, China
Primary endpoint: Pathologic Complete Response Rate (tpCR: ypT0-is/ypN0)

View Gonadorelin compound reference